Longport LPTI · USD

Its shares trade under the ticker LPTI. It has been listed since 7 September 1994. In the fiscal year to 31 December 2004, it reported revenue of $2.5m and a net loss of $633,532. At that date it held total assets of $2.7m and shareholders' equity of $903,873.

Longport, Inc. engages in the manufacture, development, marketing, and sale of high resolution ultrasound imaging systems. The company is headquartered in Chadds Ford, Pennsylvania. The firm focuses on high resolution medical ultrasound. The firm focuses on providing imaging systems that help in the prevention, assessment and treatment of medical conditions. The firm offers a high resolution ultrasound (HRUS) imaging system, EPISCAN I-200, which utilizes ultrasound to image the skin and underlying soft tissue. EPISCAN I-200 can be connected to a range of interchangeable imaging probes that enable the imaging of the skin and underlying soft tissue at frequencies between 20 megahertz and 50 megahertz. EPISCAN is utilized in a range of clinical applications, as well as in research and development. EPISCAN enables the examination of tissue at a microscopic level. Its technology is used in a range of applications, such as wound assessment and pressure ulcer prevention, dermatology, aesthetics, and research, including validation of processes and products that impact the skin.

Figures and description from our data supplier, not checked against the company's own report.

• Paul WilsonPresident, Chief Financial Officer, Director$126,819
• Michael BoydChief Executive Officer, Director
• Mr. Brian ClymerDirector
• Paul QuintavalleDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.